|
1
|
Henley SJ, Ward EM, Scott S, Ma J,
Anderson RN, Firth AU, Thomas CC, Islami F, Weir HK, Lewis DR, et
al: Annual report to the nation on the status of cancer, part I:
National cancer statistics. Cancer. 126:2225–2249. 2020. View Article : Google Scholar
|
|
2
|
Uprety D, Bista A, Chennamadhavuni A,
Niroula A, Jafri SIM, Smith A and Arjyal L: Survival trends among
patients with metastatic melanoma in the pretargeted and the
post-targeted era: A US population-based study. Melanoma Res.
28:56–60. 2018. View Article : Google Scholar
|
|
3
|
Ladányi A: Prognostic and predictive
significance of immune cells infiltrating cutaneous melanoma.
Pigment Cell Melanoma Res. 28:490–500. 2015. View Article : Google Scholar
|
|
4
|
Yang L and Zhang Y: Tumor-associated
macrophages: From basic research to clinical application. J Hematol
Oncol. 10:582017. View Article : Google Scholar
|
|
5
|
Mantovani A, Sica A, Sozzani S, Allavena
P, Vecchi A and Locati M: The chemokine system in diverse forms of
macrophage activation and polarization. Trends Immunol. 25:677–686.
2004. View Article : Google Scholar
|
|
6
|
Fuxe J and Karlsson MC: TGF-β-induced
epithelial-mesenchymal transition: A link between cancer and
inflammation. Semin Cancer Biol. 22:455–461. 2012. View Article : Google Scholar
|
|
7
|
Walia A, Yang JF, Huang YH, Rosenblatt MI,
Chang JH and Azar DT: Endostatin's emerging roles in angiogenesis,
lymphangiogenesis, disease, and clinical applications. Biochim
Biophys Acta. 1850:2422–2438. 2015. View Article : Google Scholar
|
|
8
|
Guo H, Liu Y, Gu J, Wang Y, Liu L, Zhang P
and Li Y: Endostatin inhibits the growth and migration of 4T1 mouse
breast cancer cells by skewing macrophage polarity toward the M1
phenotype. Cancer Immunol Immunother. 65:677–688. 2016. View Article : Google Scholar
|
|
9
|
Jia H, Li Y, Zhao T, Li X, Hu J, Yin D,
Guo B, Kopecko DJ, Zhao X, Zhang L, et al: Antitumor effects of
Stat3-siRNA and endostatin combined therapies, delivered by
attenuated Salmonella, on orthotopically implanted hepatocarcinoma.
Cancer Immunol Immunother. 61:1977–1987. 2012. View Article : Google Scholar
|
|
10
|
Wang H, Yang L, Wang D, Zhang Q and Zhang
L: Pro-tumor activities of macrophages in the progression of
melanoma. Hum Vaccin Immunother. 13:1556–1562. 2017. View Article : Google Scholar
|
|
11
|
Umansky V and Sevko A: Tumor
microenvironment and myeloid-derived suppressor cells. Cancer
Microenviron. 6:169–177. 2013. View Article : Google Scholar
|
|
12
|
Ruffell B and Coussens LM: Macrophages and
therapeutic resistance in cancer. Cancer Cell. 27:462–472. 2015.
View Article : Google Scholar
|
|
13
|
Skobe M, Hamberg LM, Hawighorst T,
Schirner M, Wolf GL, Alitalo K and Detmar M: Concurrent induction
of lymphangiogenesis, angiogenesis, and macrophage recruitment by
vascular endothelial growth factor-C in melanoma. Am J Pathol.
159:893–903. 2001. View Article : Google Scholar
|
|
14
|
Wang H and Zhang L, Yang L, Liu C, Zhang Q
and Zhang L: Targeting macrophage anti-tumor activity to suppress
melanoma progression. Oncotarget. 8:18486–18496. 2017. View Article : Google Scholar
|
|
15
|
Bardi GT, Smith MA and Hood JL: Melanoma
exosomes promote mixed M1 and M2 macrophage polarization. Cytokine.
105:63–72. 2018. View Article : Google Scholar
|
|
16
|
Vodovotz Y, Bogdan C, Paik J, Xie QW and
Nathan C: Mechanisms of suppression of macrophage nitric oxide
release by transforming growth factor beta. J Exp Med. 178:605–613.
1993. View Article : Google Scholar
|
|
17
|
Berking C, Takemoto R, Schaider H, Showe
L, Satyamoorthy K, Robbins P and Herlyn M: Transforming growth
factor-beta1 increases survival of human melanoma through stroma
remodeling. Cancer Res. 61:8306–8316. 2001.
|
|
18
|
Chen P, Huang Y, Bong R, Ding Y, Song N,
Wang X, Song X and Luo Y: Tumor-associated macrophages promote
angiogenesis and melanoma growth via adrenomedullin in a paracrine
and autocrine manner. Clin Cancer Res. 17:7230–7239. 2011.
View Article : Google Scholar
|
|
19
|
Xu Q, Briggs J, Park S, Niu G, Kortylewski
M, Zhang S, Gritsko T, Turkson J, Kay H, Semenza GL, et al:
Targeting Stat3 blocks both HIF-1 and VEGF expression induced by
multiple oncogenic growth signaling pathways. Oncogene.
24:5552–5560. 2005. View Article : Google Scholar
|
|
20
|
Murdoch C, Muthana M, Coffelt SB and Lewis
CE: The role of myeloid cells in the promotion of tumour
angiogenesis. Nat Rev Cancer. 8:618–631. 2008. View Article : Google Scholar
|
|
21
|
O'Reilly MS, Boehm T, Shing Y, Fukai N,
Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR and Folkman J:
Endostatin: An endogenous inhibitor of angiogenesis and tumor
growth. Cell. 88:277–285. 1997. View Article : Google Scholar
|
|
22
|
Li K, Shi M and Qin S: Current Status and
Study Progress of Recombinant Human Endostatin in Cancer Treatment.
Oncol Ther. 6:21–43. 2018. View Article : Google Scholar
|
|
23
|
Xiao L, Yang S, Hao J, Yuan X, Luo W,
Jiang L, Hu Y, Fu Z, Zhang Y and Zou C: Endostar attenuates
melanoma tumor growth via its interruption of b-FGF mediated
angiogenesis. Cancer Lett. 359:148–154. 2015. View Article : Google Scholar
|
|
24
|
Zheng AW, Jia DD, Xia LM, Jin G, Wu H and
Li T: Impact of carboplatin plus paclitaxel combined with endostar
against A375 melanoma cells: An in vitro and in vivo analysis.
Biomed Pharmacother. 83:1321–1326. 2016. View Article : Google Scholar
|
|
25
|
Cui C, Mao L, Chi Z, Si L, Sheng X, Kong
Y, Li S, Lian B, Gu K, Tao M, et al: A phase II, randomized,
double-blind, placebo-controlled multicenter trial of Endostar in
patients with metastatic melanoma. Mol Ther. 21:1456–1463. 2013.
View Article : Google Scholar
|
|
26
|
Cui C, Si L, Chi Z, Sheng X and Guo J:
Preliminary results of a phase II trial with continuous intravenous
infusion of rh-endostatin in combination with dacarbazine as the
first-line therapy for metastatic acral melanoma. Anticancer Res.
35:4350–4351. 2015.
|
|
27
|
Yang L, Xu Y, Luo P, Chen S, Zhu H and
Wang C: Baseline platelet counts and derived inflammatory
biomarkers: Prognostic relevance in metastatic melanoma patients
receiving Endostar plus dacarbazine and cisplatin. Cancer Manag
Res. 11:3681–3690. 2019. View Article : Google Scholar
|
|
28
|
Nyakas M, Aamdal E, Jacobsen KD, Guren TK,
Aamdal S, Hagene KT, Brunsvig P, Yndestad A, Halvorsen B, Tasken
KA, et al: Prognostic biomarkers for immunotherapy with ipilimumab
in metastatic melanoma. Clin Exp Immunol. 197:74–82. 2019.
View Article : Google Scholar
|
|
29
|
Liu X, Nie W, Xie Q, Chen G, Li X, Jia Y,
Yin B, Qu X, Li Y and Liang J: Endostatin reverses
immunosuppression of the tumor microenvironment in lung carcinoma.
Oncol Lett. 15:1874–1880. 2018.
|
|
30
|
Liang J, Liu X, Xie Q, Chen G, Li X, Jia
Y, Yin B, Qu X and Li Y: Endostatin enhances antitumor effect of
tumor antigen-pulsed dendritic cell therapy in mouse xenograft
model of lung carcinoma. Chin J Cancer Res. 28:452–460. 2016.
View Article : Google Scholar
|
|
31
|
Wang X, Zhan RY, Wang YY, Yan XI, Cao D,
Li Y, Wang YQ and Luo F: Endostatin improves cancer-associated
systemic syndrome in a lung cancer model. Oncol Lett. 9:2023–2030.
2015. View Article : Google Scholar
|
